Selecting the Optimal Treatment Line for CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Breast Cancer. Вопр. онкол. [Internet]. 2026 Jul. 3 [cited 2026 Oct. 13];72(3):OF-2455. Available from: https://voprosyonkologii.ru/index.php/journal/article/view/3-26-Selecting-the-Optimal-Treatment